HPV vax likely to be worth it for 12-year-old girls in the UK
NICE says no to kidney cancer drugs, sparks uproar
Prescription drug use doubled over last decade in UK seniors
Tocilizumab expected to find favour with US rheumatologists
Economic cost of Guillain Barré syndrome is substantial
Drug restriction hurts patients
Conflicts of interest common among authors of AAN guidelines
A new report has found that a high 52.3% of patients newly diagnosed with bipolar disorder
PEC news from IAC
Injectable anticoagulants may offer significant savings
Detection of early OAC remains difficult
Second-generation antipsychotic prescribing on the increase
Alveolar echinococcosis treatment cost effective in Switzerland
Linezolid a cost-effective option for skin, soft tissue infections
Financial incentives show potential to reduce care delivery inequalities
Antibacterials for UTI in those with DM more potent, prolonged
Community-based treatment of value for malaria in pregnancy
Heads up on botulinum toxin's use in migraine
Insulin admin in DM: patients prefer the pen
Pharmacist-managed anticoagulation most costly
Etanercept monotherapy, combination therapy effective in RA
Adalimumab improves QOL in AS patients
Superior QOL with sunitinib in renal cancer
Azithromycin available without prescription in UK for chlamydia
Patients sit up straight with back care programme
Prescriptions for elderly on the rise
An additional $US275 million in funding for the US FDA will not be available until March or April 2009,
US health insurance premiums have more than doubled since 1996,
Exxon Mobil Corporation has announced that it is to grant $US3.5 million to the Global Health Group at the University of California, San Francisco
The UK Department of Health (DOH) has launched an MMR catch-up campaign
The WHO has launched a new HIV/AIDS package of priority interventions
The chlamidia treatment azithromycin will soon be available in UK pharmacies